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ABSTRACT
As the drug safety and efficacy is hampered in the presence of an impurity, the international regulatory agencies laid down stringent limits for the 
control of impurities in the active pharmaceutical ingredient and pharmaceutical formulations. The conventional approaches lack the characterization 
of impurities in trace levels, due to sensitivity issues, hyphenated techniques are preferred. Among the modern hyphenated techniques, liquid 
chromatography-mass spectrometry (LC-MS) has high sensitivity and can analyze large number of organic compounds in a short period of time. In 
the present study, the impurity profiling of various drug substances and products using LC-MS about past 6 years were retrospect for its importance, 
instrumentations, and applications.
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INTRODUCTION
ICH Guidelines defines the impurity as “Any component of the 
medicinal product which is not the chemical entity defined as the active 
substance or excipients in the product” [1]. The impurity profile is the 
characterization of the identified and unidentified impurities that are 
present in the drug product [2].
The critical part of drug discovery and development is to establish a 
qualitative and quantitative impurity profile of pharmaceuticals. The 
quality of the pharmaceutical product is affected by impurities. Drug 
regulatory authorities expect to furnish in detail all impurities that 
might merge during the production and storage, which provides the 
basis for a comprehensive risk assessment.
The impurity profile can provide complete information about the 
manufacturing process, degradation process and it is diagnostic for 
the overall quality of the final product. The drug safety and quality can 
be ensured by knowing the identity of the impurities, thereby helps to 
analyze the abnormality in the production.
The impurities in pharmaceutical products are not only restricted to the 
process residual impurities, manufacturing impurities, and degradation 
products resulting from storage but also includes genotoxic impurities. 
Genotoxic impurities induce the genetic metamorphosis, chromosomal 
ruptures or chromosomal disruptions and it may cause cancer in 
humans.
If impurity profiling is not addressed properly, then the regulatory 
bodies may compel to recall the finished drug products or reject the 
approval of such products, or the drug may be kept on hold. In past few 
years the US-FDA ordered for the recall of few finished pharmaceutical 
products such as adagen (Pegademase bovine) injection, azelastine 
hydrochloride ophthalmic solution, brimonidine tartrate ophthalmic 
solution, budeprion XL (Bupropion HCl ER Tablets), prednisolone 
sodium phosphate oral solution, and topiramate 25 and 200 mg tablets 
due to the presence of impurities and degradation products [3].
The present review article endures the works of impurity profiling 
of various drug substances and product by employing the liquid 
chromatography-mass spectrometry (LC-MS) technique. The article 
mainly highlights the regulatory requirements for the control of 
impurities, columns, interface, ionization techniques, and mass 
analyzer used in the past 6 years of works on impurity profiling. Fig. 1 
represents the number of research works that are undergone in the 
field of impurity profiling using LC-MS in past 6 years.
NEED FOR THE IMPURITY PROFILING OF PHARMACEUTICAL 
PRODUCTS
Benzopyridooxathiazepine derivatives are potent, antimitotic class 
of cytotoxic compounds. The in vitro cytotoxicity studies showed 
promising results. However, the in vivo activity was poor due to drug 
decomposition and the advent of possible adverse effect showed due to 
the formation of degradation products. The study showed that 10 main 
degradation products out of which seven structures were elucidated. 
The structural comparison showed that the stability problem arises due 
to oxathiazepine ring of BZN which could have some consequences on 
storage conditions [4].
MLN9708 is a small molecule proteasome which is currently under 
investigation developed by Millennium: The Takeda Oncology Company, 
on the evaluation of impurities, found that 2, 5-dichlorobenzoyl chloride 
(DCBC) was predicted to be mutagenic. The carryover of this impurity 
into drug substance was low due to multiple acid; base workup steps. 
However, FDA suggests to provide the verification data [5].
TYPES AND SOURCES OF IMPURITIES
As per the ICH guidelines, the impurity in pharmaceutical entities and 






Organic impurities emerge during the course of production and/
or while storing new drug substance. Organic impurities are further 
classified as:
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Residual solvents are the remnants of the solvents used in the 
production of pharmaceutical entities, excipients or in the process of 
formulating the drug product. Residual solvents can be classified based 
on their toxicity levels as:
•	 Class	I	solvents:	The	use	of	solvents	present	in	this	class	must	be	
avoided. Ex: Benzene and carbon tetrachloride.
•	 Class	II	solvents:	The	use	of	solvents	present	in	this	class	must	be	
controlled. Ex: Acetonitrile, chloroform, and Hexane.
•	 Class	III	solvents:	The	solvents	present	in	this	class	have	low	lethal	
effects. Ex: Acetic acid, acetone, and formic acid.
•	 Class	IV	solvents:	The	solvents	present	in	this	class	lack	in	required	
toxicological data. Ex: Isopropyl ether, petroleum ether, and 
trifluoroacetic	acid	[6].
ICH Q3B(R2) guidelines for impurities in new drug product includes 
the impurities that arise due to deterioration of pharmaceutical entities 
or the products arise due to the reaction between drug substance and 
excipients and/or immediate packaging materials [7].
Elemental impurities in pharmaceuticals emerge from various sources, 
i.e., maybe the unconsumed catalyst that was added purposefully in the 
process of production or may be formed due to the reaction between 
the manufacturing equipment or packaging systems or exist in the drug 
product.
Elemental impurities may be classified as:
•	 Class	I	elements:	The	elements	of	this	class	have	minimal	or	no	use	
in the manufacture of medicinal products. However, if present they 





•	 Class	2B:	The	elements	of	 this	 class	have	a	 low	possibility	of	 a	
presence in the medicinal product. Ex: Ag, Rh, Au, Ru, and Pd.
•	 Class	III	elements:	The	elements	of	this	class	have	comparatively	low	
lethality by enteral route of administration, but may be toxic in case 
of inhalation and parenteral route.
•	 Other	elements:	The	elements	of	 this	 class	have	 low	elementary	
toxicity and/or difference in provincial regulations [8].
Genotoxic impurities are DNA reactive substances can injure DNA, 
when present at low levels leading to the transformation of DNA, and 
therefore, likely cause cancer [9]. They can be classified into two types,
•	 Mutagenic	carcinogens:	These	are	usually	found	by	bacterial	reverse	
mutation (mutagenicity) assay. Ex: DCBC is a mutagenic impurity 
present in MLN9708 proteasomes [5].
•	 Non-mutagenic	genotoxicants:	These	have	 threshold	mechanism,	
and at low levels, they do not pose a carcinogenic risk in humans. Ex: 
2-bromo-2-chloro-1,1-difluoroethylene	is	a	genotoxic	degradation	
product of Halothane [10].
REGULATORY REQUIREMENTS
The main objective of the regulatory bodies is to establish the safety, 
efficacy, and quality of drug products. Presence of impurities in 
the pharmaceutical entities and product may lead to undesirable 
pharmacological and toxicological effects, which in turn effect the 
safety and efficacy of the drug.
Therefore, various regulatory agencies have enforced reporting, 
identification, qualification, and quantification impurity thresholds for 
assessing the safety of pharmaceutical substances and their associated 
dosage forms. Table 1 provides various guidelines lay down by the 
various regulatory agencies.
QUALIFICATION OF IMPURITIES
Qualification is the process of obtaining and assessing data that 
provides the biological safety of a particular impurity or given 
impurity profile at the level(s) described. Table 2 provides the 
threshold levels for reporting, identification, and qualification of 
impurities [1].
CONVENTIONAL APPROACHES FOR THE ISOLATION AND 
CHARACTERIZATION OF IMPURITIES
Before two and half decades, there were no precise methods to 
isolate and characterize the impurities. The characterization of 
impurities was based on the quantification of active ingredient 
content by nonspecific titrimetric [23] and photometric methods 
(such	 as	 UV	 spectroscopy	 [24],	 IR,	 Raman	 spectroscopy	 [25],	 and	
nuclear magnetic resonance [NMR] [26]), which were supported 
by the physical constants and some limit tests for known 
impurities. Even the pharmacopeias were suggesting various 
nonspecific characterization methods for determining the content 
of active ingredients. Due to the emergence of chromatography 
in mid-19th century, various chromatographic methods such as 
capillary electrophoresis (CE) [27], Chiral separations [28], gas 
chromatography (GC) [29], high-pressure liquid chromatography 
(HPLC) [30], supercritical fluid chromatography [31], and Thin-layer 
chromatography (TLC) [32] were employed for the separation of 
various impurities in drug substance and products. Followed by the 
isolation/enrichment/synthesis by solid phase extraction, liquid–
liquid extraction, accelerated solvent extraction, supercritical fluid 
extraction, column chromatography, flash chromatography, TLC, etc., 
and	later	spectrophotometric	characterization	of	impurities	using	UV	
spectroscopy, IR, Raman spectroscopy, and NMR.
STRUCTURAL CHARACTERIZATION USING MODERN HYPHENATED 
TECHNIQUES
As the process of impurity profiling takes more time for the 
identification, separation, characterization and quantification using 
conventional methods, researchers prefer to use one equipment 
for all the purpose. This can be achieved by employing the modern 
hyphenated techniques that possess both the separation and 
characterization of impurities in single equipment. The commonly used 
modern hyphenated techniques for the isolation and characterization 
are as follows GC-MS [33], LC-MS [34], LC-MS-MS [35], LC-inductively 
coupled plasma (ICP)-MS [36], CE-ICP-MS [37], etc.
HISTORY OF LC-MS
The mass spectrometer is considered as a better detector for LC 
applications as LC requires sensitivity, specificity, and versatility to 
provide both qualitative and quantitative analysis of a wide variety 
of compounds. Mass spectrometer was discovered by Francis Aston 
in	 early	 1920s	 based	 on	Thomson’s	 discovery	 of	 the	 electron.	 Victor	
Tal’roze was pioneer in attempting to couple LC with MS in 1960s by 
directly spraying liquid into the ionization chamber of low-pressure 
electron impact mass spectrometer. In the same year, Malcom Dole 
demonstrated electron spray ionization. In early 1970s Tal’roze 
provided three strategies to address the interface issue, they are 
atmospheric pressure chemical ionization, moving wire system, which 
led to the moving belt interface and direct liquid introduction [38] 
Table 3.
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ADVANTAGES OF USING LC-MS OVER OTHER ANALYTICAL 
TECHNIQUES
Most of the analytical techniques lack sensitivity and are not able 
to deduce the structure of the unknown impurities. Hence, LC-MS 
is considered as an essential and versatile tool for the structural 
elucidation of impurities. It is handy and efficient since it provides rapid 
and effective separation. The structures from the unknown impurities 
can be obtained by characterization on the basis of mass separations 
from the drug in the form of ions; molecular formulae can be determined 
from specific mass measurements [39]. As the instrument has high 
sensitivity, it can detect impurities in trace levels up to fematogram 
(1fg=10−15 g) level in bulk samples [40]. The structural elucidation 
with LC-MS can help in the determination of route cause for arise of 
impurities and thereby helps in controlling the impurity levels in the 
drug substance or product.
INSTRUMENTATION OF LC-MS
LC-MS instrumentation can be classified into two parts, i.e., HPLC 
system and mass spectrometry [41]. The LC-MS instrumentation is 
briefly given in Fig. 2.
HPLC system
The HPLC system works as follows, the mobile phase is pumped from a 
reservoir and the sample is injected through injector which enters the 
column along with mobile phase. The separation occurs in the column, 
and the separated constituents are detected by the detectors. The most 
commonly used pumps are piston pumps. The pistons are commonly 
constructed from beryl glass, called sapphire pistons. The introduction 
of sample successfully into the columns is achieved using loop injectors 
and valve injectors [41].
In most of the studies, 0.1% aqueous formic acid with the organic 
solvents with or without formic acid was used, as they have various 
advantages when compared to acetic acid and trifluoroacetate. Formic 
acid has less molecular weight than acetic acid and trifluoroacetate; 
hence, they cause less interference in the mass spectrum. For the 
analysis of basic compounds, acidic mobile phases are needed. The use 
of low pH mobile phase keeps residual silanol in an undissociated state. 
Formic acid has lower contamination levels than acetic acid [42].
Column is considered as the heart of HPLC system. The most commonly 
used silica column is C18 column or octadodecyl silica column. It is a 
non-polar organic phase chemically bonded to silica. In few cases, C8 
columns are preferred. Table 4 gives the various commercially available 
C18 and C8 columns which were used in the impurity profiling works 
carried out from 2012 to 2017.
The detectors in LC-MS system is mass spectrometers. However, other 
HPLC detectors are either placed in series or a part of mobile phase can 
be diverted to mass spectrometer by employing splitters. Secondary 
detectors used may be refractive index detector, conductivity detector, 
ultraviolet detector or fluorimeters.
Table 1: International guidelines outlining the regulatory requirements for the control of impurities in drug substances and drug 
products
Regulatory agency Guidelines Issue date References
ICH (USA, Europe and Japan) Q3A (R2) Impurities in new drug substances 25th October 2006 [1]
Q3B (R2) Impurities in new drug products 2nd June 2006 [7]
Q3C (R6) Impurities guideline for residual solvents 20th October 2016 [6]
Q3D Guideline for elemental impurities 16th December 2014 [8]
M7(R1) Assessment and control of DNA 
reactive (mutagenic) impurities in pharmaceuticals to limit 
potential carcinogenic risk
31st March 2017 [9]
EMA (Europe) EMA/CHMP/CVMP/QWP/450653/2006	Assessment	of	the	
quality of medicinal products containing existing/known 
active substances
9th February 2009 [11]
CPMP/QWP/1529/04	Control	of	impurities	of	
pharmaceutical substances




28th June 2006 [13]
EMEA/CHMP/SWP/4446/2000	Guideline	on	the	
specification limits for residues of metal catalyst or metal 
reagent
21st February 2008 [14]
EMA/CHMP/CVMP/QWP/199250/2009	Guideline	on	
setting specification for related impurities in antibiotics
30th June 2013 [15]
US-FDA NDAs: Impurities in new drug substances February 2000 [16]
ANDAs: Impurities in new drug substances June 2009 [17]
ANDAs: Impurities in new drug products November 2010 [18]
Elemental impurities in drug products (draft) June2016 [19]
Genotoxic and carcinogenic impurities in drug substances 
and products: Recommended approach (draft)
December 2008 [20]
Health Canada Impurities in existing drug substances and products 6th September 2005 [21]
TGA (Australia) Guidance 18: Impurities in drug substances and drug 
products
9th August 2013 [22]
Table 2: Reporting, identification and qualification thresholds for the impurities in pharmaceuticals
Maximum Daily dose Reporting threshold Identification threshold Qualification threshold
≤2	g/d 0.05% 0.10% or 1.0 mg/d 
intake (whichever is maximum)
0.15% or 1.0 mg/day intake (whichever 
is maximum)
>2 g/d 0.03% 0.05% 0.05%
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Mass spectrometry
The role of interface in the LC-MS is that it must specifically retain the 
compound of interest by removing the volatile solvents and additives. 
As most of the target compounds are uncharged in the HPLC eluent, the 
interface helps in the ionization of the molecules. Atmospheric pressure 
interfaces for LC-MS system are of two types, electron spray and ion 
spray or atmospheric pressure chemical ionization. The commercially 
built mass spectrometers contain both interfaces which allow the 
switching of modes based on the area of interest. Positive ionization 
mode gives rise to molecular ions and solvent adducts, whereas, 
negative ionization mode gives rise to deprotonated ions. Electron 
spray interfaces can be mainly used for compounds with high polarity 
and ionization properties. Ion spray interfaces are recommended when 
the flow rate from the HPLC system is up to 2 mL/min, and the effluent 
polarity is very low [41].
The heart of mass spectrometer is mass analyzer. Quadrupole is less 
expensive mass analyzer whereas ion trap analyzers are 10 - 100 times 
more sensitive than quadruple and they require less maintenance. Time 
of flight mass analyzers can analyze very large biological molecules. 
Fourier transform analyzers are non-destructive LC-MS detectors as 
they produce mass spectra using ion cyclotron resonance. But in most 
of the impurity profiling studies, hybrid mass analyzers were employed. 
The determination of trace levels of impurities cannot be achieved 
using single analyzer. Few of the hybrid mass analyzers employed in 
the studies were as follows Triple Quadrupole, Orbitrap, Q-Trap, Q-IT, 
Q-TOF, IT-TOF, etc. The commonly used detectors of ions are electron 
multiplier tube, faraday cup, scintillation counter, etc. [41].
UTILIZATION OF LC-MS IN IMPURITY PROFILING
Role of LC-MS in process related impurity profiling
Process-related impurities are potential impurities that emerge during 
the API manufacturing process which includes the starting material, 
intermediate material, and by-products, which may be organic or 
inorganic in nature.
Impurity analysis of bitespiramycin by Ming et al. [40], provided 
information on 9 major components, 5 minor components, 12 new 
related substances, and 12 unknown related substances which were 
partially characterized. Few of the proposed related substances 
characterized were 4-propionyl SPM I, 4-(iso)butyryl SPM I, 4-(iso)
hexadienyl SPM II, etc.
The process of structural elucidation can be simplified by employing 
various characterization tools. Andras et al. [47] were able to reveal the 
presence of a novel by-product, 4-phenyl-naphtopyran indapoxetine 
by utilizing the results obtained from NMR along with the results 
obtained from LC-MS for the structural elucidation. In the same 
way, Musty et al. [90] were able to characterize two process-related 
impurities using NMR results along with LC-MS.
Few drugs of microbial origin such as antibiotics gain impurities during the 
process of fermentation. Chopra et al. [86] analyzed the impurities in tylosin. 
The study revealed the presence of 4 major impurities and 23 unknown 
impurities arised during the process of fermentation. The unknown 
impurities were easily characterized and quantified using LC-MS technique.
Role of LC-MS in impurity profiling of product-related impurities
Product-related impurities emerge during the manufacture and/
or storage due to the molecular variation of the intended product 
structure and degradation products. In most of the cases, product-
Fig. 1: Articles published on the liquid chromatography-mass 
spectrometry in the impurity profiling of pharmaceuticals
Fig. 2: Instrumentation of liquid chromatography-mass 
spectrometry
Table 3: List of discoveries in the field of LC-MS
Year Discoveries
1907 Discovery of electron by Thomson
1913 First spectrum that demonstrates two different 
isotopes of Neon by Thomson
1919 Development of First mass spectrometer by 
Francis Astom




Late 1960s Demonstration of Electron spray at 
atmospheric pressure
Early 1970s APCI, the moving wire system and direct liquid 
introduction	were	studied	by	Victor	Tol’roze
1979 Incorporation of direct liquid injection probe 
approach into first available LC-MS interfaces 
by Hewlett-packard
1980s Commercialization of a moving belt LC-MS 
interface by Finnigan
1984 Development of thermospray LC-MS by Marvin 
Vestal
1989 Commercialization of triple quadrupole LC-MS/
MS by AB Sciex
LC-MS: Liquid chromatography-mass spectrometry
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related impurities emerge from the reaction of drug component with 
excipients such reactions were observed in gabapentin capsules 
where GBP-Lactose conjugate impurity was formed. This impurity was 
characterized by Buchi et al. [87] by employing LC-MS technique.
The storage of formulation in extreme conditions may give rise 
to various product-related impurities, which was observed in the 
parenteral infusion of an amino acid supplement containing L-alanyl-
L-glutamine by Simone et al. [63]. Authors were able to identify and 
quantify 21 impurities in the infusion after stress studies by employing 
liquid chromatography tandem mass spectrometry.
Role of LC-MS in the profiling of degradation of drug substance
Degradation is the inability of a particular drug substance in a specific 
container to remain within particular chemical, microbiological, 
therapeutical, physical, and toxicological specifications.
Development of degradation pathway can provide the information on 
possible impurities that may arise in the drug substance. In this regard, 
Thomas et al. [83] subjected eslicarbazepine drug to forced degradation 
studies and developed degradation pathway by separating the impurities 
by	 LC-UV	 followed	 by	 characterization	 using	 LC-MS/MS,	 NMR,	 and	
IR spectroscopy. Trandolapril degradation pathway was developed 
by Dendeni et al. [39], included the mechanism of degradation under 
chemical stress in both neutral and acidic conditions using UPLC-
ESI-tandem mass spectrometry. In the same way, Mayuri et al. [91] 
developed the degradation pathway of Fenoxazoline by employing 
HPLC-UV	 for	 separation	 and	 LC-MS/MS	 for	 the	 characterization	 of	
degradation products.
Role of LC-MS in the profiling of degradation of drug product
Development of degradation pathway is important not only in drug 
substances but also in drug products. Nagdeep et al. [57] employed 
LC/ESI-MS/MS method for developing degradation pathway of 
dabigatran etexilate in both bulk drug and capsule formulation. Authors 
were able to identify 15 impurities among which two impurities were 
unknown. Degradation pathway was developed for the unknown 
impurities based on the information obtained from LC-MS, FTIR, 
Proton, and 13C NMR spectroscopies.
Degradation of the drug product may also occur during the process 
of administration. Tiaziana et al. [75] identified degradation products 
for sodium risedronate granules for oral solution and effervescent 
tablets by carrying out oxidative degradation study. Authors employed 
LC-ESI-MS for determining the main degradation product.
Role of LC-MS in the profiling of genotoxic impurities
Genotoxic impurities cause the deleterious change in the genetic 
material regardless of the mechanism by which the change takes place.
Katerina et al. [59] and Szekely et al. [45] extensively worked on 
the analysis of potential genotoxic impurities in meropenem and 
glucocorticoids, respectively. Use of LC-MS/MS in the study helped in 
identifying genotoxic impurities in trace levels, reducing the cost per 
Table 4: List of columns used in the impurity separation
Manufacturer Column name Column dimensions References
Agilent Zorbax C18 Column 50 mm×3 mm ID, 3.5 µm dp [43]
Poroshell 120SB C18 Column 150 mm×4.6 mm ID, 2.7 µm dp [44]
Zorbax Eclipse Plus C18 Column 100 mm×4.6 mm ID, 3.5 µm dp [47]
Varian	Polaris	C18	A	Column 150 mm×2 mm ID, 5 µm dp [48]
Poroshell 120EC C-18 Column 100 mm×4.6 mm ID, 2.7 µm dp [5]
Zorbax SB C18 column 150 mm×4.6 mm ID, 5 µm dp [49]
Eclipse Plus C18 RRHD Column 100 mm×2.1 mm ID, 1.8 µm dp [50]
Poroshell HPH C18 Column 50 mm×2.1 mm ID, 2.7 µm dp [51]
Zorbax SB-CN Column 200 mm×4.6 mm ID, 5 µm dp [52]
Zorbax RX C8 Column 250 mm×4.6 mm ID, 5 µm dp [53]
Akzo Nobel Kromosil 100-5 C18 Column 150 mm×4.6 mm ID, 5 µm dp [54]
Kromosil C18 Column 250 mm×4.6 mm ID, 5 µm dp [55]
Discovery C8 Column 25 cm×4.6 mm ID, 5 µm dp [56]
GL Sciences Inertsil	ODS-	3V	Column 250 mm×4.6 mm ID, 5 µm dp [57]
Grace Alltima C18 Column 250 mm×3 mm ID, 5 µm dp [58]
Macherey-Nagel Nucleosil C18 Column 150 mm×4.6 mm ID, 5 µm dp [59]
Merck LiChrospher RP18 column 250 mm×2 mm ID, 5 µm dp [60]
Nacalai Tesque Cosmosil C18 Column 250 mm×4.6 mm ID, 5 µm dp [61]
Phenomenex Gemini C18 Column 50 mm×2 mm ID, 3 µm dp [45]
Gemini C18 Column 150 mm×3 mm ID, 3 µm dp [62,63]
Gemini NX C18 Column 250 mm×4.6 mm ID, 5 µm dp [64-68]
Luna C18 Column 250 mm×4.6 mm ID, 10 µm dp [69]
Luna C18 Column 150 mm×3 mm ID, 5 µm dp [70]
Gemini C18 Column 150 mm×4.6 mm ID, 3 µm dp [71]
Shiseido CAPCELL PAK C18 Column 150 mm×2 mm ID, 5 µm dp [44,72]
Shimadzu Shim pack GISS C18 Column 50 mm×2.1 mm ID, 1.9 µm dp [73]
Shim pack XR-ODS Column 75 mm×3 mm ID, 2.2 µm dp [74]
Supelco Ascentis Express HILIC Column 150 mm×2.1 mm ID, 2.7 µm dp [75]
Thermo Fischer Scientific Hypersil BDS C18 Column 250 mm×4.6 mm ID, 5 µm dp [76,77]
Thermo Hypersil Gold Column 100 mm×2.1 mm ID, 1.9 µm dp [78]
Welch Xtimate C18 Column 250 mm×4.6 mm ID, 5 µm dp [79]
Xtimate SEC-120 Column 30 cm×7.8 mm ID, 5 µm dp [80]
Waters Acquity HSS T3 C18 Column 100 mm×2.1 mm ID, 1.7 µm dp [4]
Acquity UPLC BEH C18 Column 150 mm×2.1 mm ID, 1.7 µm dp [46]
Acquity UPLC BEH C18 Column 100 mm×2.1 mm ID, 1.7 µm dp [39,81]
Xterra RP18 Column 250 mm×4.6 mm ID, 5 µm dp [82,83,84]
Sunfire C18 Column 250 mm×4.6 mm ID, 5 µm dp [85]
Xterra C18 Column 250 mm×2.1 mm ID, 5 µm dp [86]
Spherisorb C8 Column 250 mm×4.6 mm ID, 5 µm dp [87]
BEH Glycon Column 100 mm×2.1 mm ID, 1.7 µm dp [88]
YMC C18 Pro Column 150 mm×4 mm ID, 3 µm dp [89]
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analysis, ultra-low limit of quantitation and obtaining high throughput 
results.
CONCLUSION
The above discussion, explains the importance of impurity profiling 
and various guidelines were enforced by various regulatory bodies to 
maintain the safety and quality of pharmaceutical products. The study 
also reveals that LC-MS is a better option for the structural elucidation 
of both known and unknown impurities. Most of the research work on 
impurity profiling includes the use of C-18 column and mobile phases 
containing 0.1–1% of formic acid. Electron spray ionization under 
atmospheric pressure was preferred by the researchers for the impurity 
profiling mostly in positive ionization mode. Hybrid analyzers were 
preferred especially Q-Trap and Q-TOF. The present study may help 
the researchers in the selection of column, mobile phase, ionization 
technique, and analyzers for the LC-MS instrument and understand the 
ease with which the impurity profiling may be carried out using LC-MS.
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